Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis (EXEL), an oncology-focused biotechnology firm, is highlighted as a strong momentum stock by Zacks, despite its current #3 (Hold) Zacks Rank, due to its top-tier 'A' Momentum Style Score and 'B' VGM Score. The company has demonstrated robust earnings trends, with seven analysts revising fiscal 2025 earnings estimates higher in the last 60 days, increasing the consensus to $2.70 per share, and maintaining an average earnings surprise of +20.7%, indicating potential for continued positive performance.

Analysis

Exelixis, Inc. (EXEL) presents a noteworthy profile for momentum-oriented investors, characterized by strong underlying earnings trends despite a neutral Zacks #3 (Hold) rank. The oncology-focused biotechnology firm has been assigned a top-tier 'A' for its Momentum Style Score and a solid 'B' for its combined VGM score. This positive momentum is supported by tangible analyst actions; over the last 60 days, seven analysts have revised their fiscal 2025 earnings estimates higher, pushing the consensus estimate up by $0.06 to $2.70 per share. Furthermore, Exelixis has demonstrated a consistent ability to outperform expectations, boasting an average earnings surprise of +20.7%. While recent share price movement has been modest, with a 0.4% gain over the past four weeks, the positive revisions in its earnings outlook suggest a favorable underlying trend that is attracting analyst attention.

Key Decisions for Investors

• Investors with a momentum-focused strategy should consider EXEL, as its 'A' Momentum Score and upward earnings estimate revisions for FY2025 signal a potentially favorable trend.
• The neutral Zacks #3 'Hold' rank serves as a caution; a potential upgrade to a 'Buy' or 'Strong Buy' would provide a stronger confirmation signal and should be monitored closely.
• Given the emphasis on earnings, investors should track whether the company can sustain its significant average earnings surprise of +20.7% in subsequent quarters, as this is a key driver of the positive thesis.